We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current GSK market cap is 63.6B. The company's latest EPS is GBP 0.6211 and P/E is 24.70.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 34.1B | 34.11B | 34.91B | 30.33B | 31.38B |
| Operating Income | 5.08B | 6.67B | 8.43B | 7.35B | 4.02B |
| Net Income | 5.75B | 4.39B | 14.96B | 4.93B | 2.58B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 80.43B | 79.1B | 60.15B | 59.01B | 59.46B |
| Total Liabilities | 59.62B | 57.76B | 50.05B | 46.21B | 46.38B |
| Total Equity | 20.81B | 21.34B | 10.1B | 12.8B | 13.09B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 8.44B | 7.95B | 7.4B | 6.77B | 6.55B |
| Investing | 2.16B | -1.78B | -8.77B | -1.6B | -1.23B |
| Financing | -10.13B | -7.59B | 823M | -5.64B | -4.73B |
| Market Cap | 63.6B |
| Price to Earnings Ratio | 24.70 |
| Price to Sales Ratio | 2.03 |
| Price to Cash Ratio | 16.43 |
| Price to Book Ratio | 4.86 |
| Dividend Yield | 4.17% |
| Shares Outstanding | 4.15B |
| Average Volume (1 week) | 9.98M |
| Average Volume (1 Month) | 8.38M |
| 52 Week Change | -9.75% |
| 52 Week High | 1,820.00 |
| 52 Week Low | 1,282.50 |
| Spread (Intraday) | 1 (0.07%) |
| Company Name | Gsk Plc |
| Address |
79 new oxford street london WC1A 1DG |
| Website | https://www.gsk.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
